ECSP22067279A - Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo - Google Patents

Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo

Info

Publication number
ECSP22067279A
ECSP22067279A ECSENADI202267279A ECDI202267279A ECSP22067279A EC SP22067279 A ECSP22067279 A EC SP22067279A EC SENADI202267279 A ECSENADI202267279 A EC SENADI202267279A EC DI202267279 A ECDI202267279 A EC DI202267279A EC SP22067279 A ECSP22067279 A EC SP22067279A
Authority
EC
Ecuador
Prior art keywords
purification
chemical formula
synthesis
sglt inhibitor
compound
Prior art date
Application number
ECSENADI202267279A
Other languages
English (en)
Inventor
Youn Jung Yoon
Hee Kyoon Yoon
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of ECSP22067279A publication Critical patent/ECSP22067279A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/02Phosphorylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención proporciona un producto intermedio útil para la síntesis de un inhibidor de SGLT y un método para preparar un inhibidor de SGLT usando el mismo. Según la presente invención, al desarrollar un compuesto de fórmula química 5 correspondiente a un producto intermedio novedoso, puede resolverse la dificultad de purificación con los procedimientos existentes, pueden satisfacerse los requisitos de calidad para sustancias relacionadas con una única etapa de purificación y puede resolverse el problema de control de calidad en cada etapa realizando varias etapas in situ. El método para sintetizar un compuesto de fórmula química 1 mediante el uso de un compuesto de fórmula química 5, según la presente invención, permite la purificación en la etapa de síntesis de un compuesto de fórmula química 5, resolviendo de ese modo los problemas de los procedimientos de síntesis existentes, en los que los requisitos de calidad para sustancias relacionadas eran difíciles de controlar etapa por etapa debido a un procedimiento continuo, y minimizando la cantidad de sustancias relacionadas en el producto final. Además, a medida que aumenta el número de etapas de purificación, el procedimiento puede simplificarse porque la purificación no se realiza necesariamente dos o más veces en una etapa como en la técnica anterior, maximizando de ese modo el rendimiento de producción de un derivado de difenilmetano según la fórmula química 1.
ECSENADI202267279A 2020-02-27 2022-08-26 Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo ECSP22067279A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200024525 2020-02-27

Publications (1)

Publication Number Publication Date
ECSP22067279A true ECSP22067279A (es) 2022-09-30

Family

ID=77490302

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202267279A ECSP22067279A (es) 2020-02-27 2022-08-26 Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo

Country Status (16)

Country Link
US (3) US12497390B2 (es)
EP (1) EP4112612B1 (es)
JP (1) JP7442663B2 (es)
KR (1) KR102572714B1 (es)
CN (1) CN115087649B (es)
AU (1) AU2021225706B2 (es)
BR (1) BR112022014762A2 (es)
CA (1) CA3169604C (es)
CL (1) CL2022002326A1 (es)
CO (1) CO2022011686A2 (es)
EC (1) ECSP22067279A (es)
ES (1) ES3056001T3 (es)
MX (1) MX2022010220A (es)
PE (1) PE20221498A1 (es)
SA (1) SA522440295B1 (es)
WO (1) WO2021172955A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102837948B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837941B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102853437B1 (ko) * 2024-11-13 2025-09-04 대웅바이오(주) 연속반응 공정을 이용한 이나보글리플로진 합성방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530124A (en) * 1994-06-30 1996-06-25 The Dupont Merck Pharmaceutical Company Method for preparing cyclic ureas and their use for the synthesis of HIV protease inhibitors
PT2324002T (pt) * 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2
KR101513234B1 (ko) * 2010-09-10 2015-04-17 주식회사 녹십자 Sglt2 억제제로서의 신규 티오펜 유도체 및 이를 포함하는 약학 조성물
CN103596564B (zh) * 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
CN105121434B (zh) * 2014-03-19 2017-08-29 杭州普晒医药科技有限公司 坎格列净一水合物及其晶型、它们的制备方法和用途
WO2016098016A1 (en) 2014-12-17 2016-06-23 Dr. Reddy’S Laboratories Limited Process for the preparation of sglt2 inhibitors
JP6763978B2 (ja) 2016-06-17 2020-09-30 デウン ファーマシューティカル カンパニー リミテッド ジフェニルメタン誘導体の製造方法
CN108530408A (zh) 2018-04-13 2018-09-14 海门慧聚药业有限公司 制备达格列净的方法
ES2980368T3 (es) * 2018-08-13 2024-10-01 Daewoong Pharmaceutical Co Ltd Método para producir un intermediario útil para la síntesis de inhibidor de SGLT

Also Published As

Publication number Publication date
AU2021225706B2 (en) 2024-06-13
AU2021225706A1 (en) 2022-09-01
CN115087649A (zh) 2022-09-20
CA3169604A1 (en) 2021-09-02
JP2023514754A (ja) 2023-04-07
EP4112612A4 (en) 2024-04-03
US12497390B2 (en) 2025-12-16
MX2022010220A (es) 2022-10-10
US20260078109A1 (en) 2026-03-19
CO2022011686A2 (es) 2022-08-30
ES3056001T3 (en) 2026-02-17
CA3169604C (en) 2025-03-11
PE20221498A1 (es) 2022-09-29
US20260085065A1 (en) 2026-03-26
EP4112612A1 (en) 2023-01-04
CN115087649B (zh) 2024-07-05
BR112022014762A2 (pt) 2022-10-11
CL2022002326A1 (es) 2023-02-10
EP4112612B1 (en) 2025-10-22
US20230096670A1 (en) 2023-03-30
KR102572714B1 (ko) 2023-08-31
SA522440295B1 (ar) 2025-04-10
KR20210109476A (ko) 2021-09-06
JP7442663B2 (ja) 2024-03-04
WO2021172955A1 (ko) 2021-09-02

Similar Documents

Publication Publication Date Title
ECSP22067279A (es) Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo
MX2012003048A (es) Procesos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo.
AR061112A1 (es) Procedimientos para la produccion de derivados de benzopiran-2-ol, fesoterodina y un derivado de la tolterodina e intermediarios de sintesis de los citados procesos.
EA202091466A1 (ru) Синтез сокристалла 1:1:1 1-циано-2-(4-циклопропилбензил)-4-(-d-глюкопираноз-1-ил)бензола, l-пролина и воды
MX2022003023A (es) Compuestos heterociclicos.
DE60316573D1 (de) Verfahren und vorrichtung für die herstellung einer ein bituminöses bindemittel enthaltenden baumischung
EP4286393A4 (en) NEW METHOD FOR THE PRODUCTION OF AN ANTIBODY-IMMUNE STIMULATOR CONJUGATE
BR112019005294A2 (pt) processo para preparar (±)-2-exo-(2-metilbenzilóxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano de fórmula (i) e método para prevenir ou reduzir a formação de depósitos no interior de um reator
EP3974047A4 (en) METHOD OF MANUFACTURE OF PURIFIED RESIST COMPOSITION PRODUCT, RESIST SAMPLE MANUFACTURING METHOD AND PURIFIED RESIST COMPOSITION PRODUCT
EA202191502A1 (ru) Способ получения апиксабана
AR117834A1 (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de síntesis
AR128407A1 (es) Compuesto, método de preparación del mismo y aplicación del compuesto en la preparación del producto intermedio de biciclopirona
MX2019013872A (es) Metodo para producir material no tejido de celulosa sintetizada bacterianamente.
PH12021550297A1 (en) Preparation of intermediate useful for synthesis of sglt inhibitor
DE60102008D1 (de) Herstellungsverfahren für ein bekanntes terazolderivat
MX2018010128A (es) Toxina nueva y metodo de preparacion de un intermediario de la misma.
MX2022001845A (es) Metodo para eliminar del vidrio metales perturbadores tales como hierro.
EP3954436A4 (en) PROCESS FOR MANUFACTURING A BIO-TISSUE-LIKE STRUCTURE
CY1125566T1 (el) Μεθοδος παραγωγης της ελαιοκανθαλης, της ελαιασινης και των αναλογων τους
DE602005013007D1 (de) Verfahren zur herstellung von lactonen
EP4342580A4 (en) 1,3-BUTADIENE SYNTHESIS CATALYST, PROCESS FOR PRODUCING SAME AND PROCESS FOR PRODUCING 1,3-BUTADIENE
AR131159A1 (es) Método para sintetizar la fosforamidita de nucleótidos de análogo de fosfato-4’
EP4108652A4 (en) PROCESS FOR PRODUCING ALCOHOL
FR848739A (fr) Procédé de fabrication de persels, tels que les persulfates, par électrolyse
BRPI0514000A (pt) método para a produção de derivados de diarilcicloalquila